An observational study in Temporomandibular Disorders (TMD) and Pregnancy, sponsored by Zeynep Serra Kalkan. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Zeynep Serra Kalkan · Observational
Among 150 studies in Temporomandibular Joint Disorders with a site in Turkey — 27 open to participants now, 28 under way, none of them phase 3. Temporomandibular Joint Disorders · Turkey.
Among the 150 studies in Temporomandibular Joint Disorders with a site in Turkey, this one is the 44th largest by planned enrollment of the 70 observational ones, is one of 15 that started in 2026, is one of 70 observational ones, reaches primary completion later than 27 of the 27 other live ones, and was the 147th registered.
591 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
This study's planned enrollment of 60 is below the median of 91 across 165 observational studies indexed under Temporomandibular Joint Disorders.
Browse Temporomandibular Joint Disorders studies →27 of the 150 studies in Temporomandibular Joint Disorders with a site in Turkey are open now, in 1 country. Each count lists the studies.
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →150 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 15 started in 2026.
Median enrollment 45 across the 80 interventional studies, 78 across the 70 observational. Of the 114 that completed or were terminated, 4 (4%) have results posted.
None of the 150 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zeynep Serra Kalkan as lead sponsor.
Zeynep Serra Kalkan has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Temporomandibular Joint Disorders with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577687Yuzuncu Yil UniversityEffect of Emg-Biofeedback and Multimodal Exercise on Temporomandibular Joint Dysfunction | 2026-12-15 |
| NCT07850674Mustafa Kemal UniversitySpinal Mobility, Rigidity, and Kinesiophobia in PD and TMD | 2026-12-23 |
| NCT07576582Uşak UniversityPeloid Therapy in Temporomandibular Joint Dysfunction | 2027-01-01 |
| NCT07791173Zeynep Serra KalkanEvaluation of Temporomandibular Disorders During Pregnancy | 2027-03 |
Among the 150 studies in Temporomandibular Joint Disorders with a site in Turkey, from their registry updates:
This study aims to evaluate how temporomandibular disorders (TMD) - a condition affecting the jaw joint and chewing muscles - change during pregnancy. The same pregnant women will be assessed twice: once in the first trimester (weeks 8-12) and again in the third trimester (weeks 28-32). At each visit, researchers will examine jaw function and pain, and collect blood samples to calculate inflammation markers from routine complete blood counts. Where participants additionally consent, blood samples will also be used to measure hormone levels (estrogen and progesterone). Participants will also complete questionnaires about pain, stress and jaw-related habits. The goal is to better understand whether hormonal and inflammatory changes during pregnancy are associated with the development or worsening of TMD symptoms.
Pregnancy is characterized by significant hormonal, biomechanical, and psychosocial changes. Rising estrogen and progesterone levels may affect connective tissue, joint stability, and pain perception, and estrogen receptors have been identified in temporomandibular joint tissue, suggesting a biological pathway linking pregnancy hormones to TMD symptoms.
This prospective longitudinal cohort study will enroll 60 pregnant women aged 18-40 who are in their first trimester at the time of enrollment. Clinical TMD findings will be assessed using the DC/TMD short protocol; pain and functional limitation will be measured with the Graded Chronic Pain Scale (GCPS) and Jaw Functional Limitation Scale-8 (JFLS-8); psychosocial status will be assessed with the Perceived Stress Scale (PSS-10) and Oral Behaviors Checklist (OBC). Venous blood samples will be drawn at both visits as part of routine complete blood count testing, from which a Systemic Immune-Inflammation Index (SII) will be calculated for all participants. Where participants provide additional consent, blood samples will also be used to measure serum estrogen and progesterone levels; hormonal data may therefore not be available for all enrolled participants. Occlusal relationships (Angle classification) will be recorded as a secondary, exploratory variable. The primary outcome is the change in GCPS pain intensity score between the first and third trimester.
Pregnant women aged 18-40 years presenting to the Obstetrics and Gynecology outpatient clinic during their first trimester, recruited consecutively based on eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, singleton pregnant women aged 18-40 years, enrolled in their first trimester (weeks 8-12) and followed prospectively through the third trimester (weeks 28-32). Participants underwent clinical DC/TMD examination, pain and functional assessment (GCPS, JFLS-8), psychosocial questionnaires (PSS-10, OBC), and blood collection for complete blood count (with SII calculation) at both visits. Where additional consent was provided, blood samples were also used to measure serum estrogen and progesterone levels. No intervention was administered; this is a purely observational cohort.
Change in Graded Chronic Pain Scale - Characteristic Pain Intensity (GCPS-CPI) Score
The GCPS-CPI subscale assesses characteristic pain intensity related to temporomandibular disorders. Scores range from 0 to 100, with higher scores indicating greater pain intensity. The change between the first and third trimester assessments will be evaluated.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32), approximately 20-24 week
Change in Jaw Functional Limitation Scale-8 (JFLS-8) Score
JFLS-8 assesses jaw-related functional limitation in mastication, mobility, and verbal/emotional expression. Higher scores indicate greater functional limitation.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32)
Change in DC/TMD Axis I Clinical Findings
Clinical findings including maximum mouth opening, lateral/protrusive movement range, palpation pain, and joint sounds, assessed per the DC/TMD short protocol.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32
PSS-10
PSS-10 measures the degree to which situations in one's life are appraised as stressful. Higher scores indicate greater perceived stress.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32)
Change in Systemic Immune-Inflammation Index (SII)
SII will be calculated from routine complete blood count parameters (neutrophil, lymphocyte, and platelet counts) as: SII = (Platelet count × Neutrophil count) / Lymphocyte count.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32)
Change in Serum Estrogen and Progesterone Levels
Venous blood samples will be analyzed for serum estrogen and progesterone concentrations, where participants provide additional consent. Hormonal data may not be available for all enrolled participants.
Time frame: From first trimester (weeks 8-12) to third trimester (weeks 28-32)
Plan to share: No — Individual participant data will not be shared due to data protection and confidentiality commitments made to participants during the informed consent process, in accordance with Turkish Personal Data Protection Law (KVKK).
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
Of 57 non-industry observational studies under Temporomandibular Joint Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 6 months is below that.
Counting every sponsor, half of 59 studies reached it within 12 months; a quarter within 5 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →